Welcome to our dedicated page for SOPHiA GENETICS SA Ordinary Shares news (Ticker: SOPH), a resource for investors and traders seeking the latest updates and insights on SOPHiA GENETICS SA Ordinary Shares stock.
SOPHiA GENETICS SA (Nasdaq: SOPH) is a leader in the field of data-driven medicine, leveraging cutting-edge technology to advance healthcare. Based in Switzerland, the company is renowned for its high medical standards and precision. SOPHiA GENETICS has built the SOPHiA DDM™ Platform, a cloud-based SaaS platform designed to analyze complex genomic and multimodal data, delivering valuable insights for clinical and life sciences research.
Through its innovative platform, SOPHiA GENETICS supports healthcare professionals in over 100 hospitals globally, enabling them to perform faster and more accurate diagnoses using next-generation sequencing (NGS) analytics. The platform also facilitates knowledge sharing within the largest clinical genomics community.
Recently, SOPHiA GENETICS has made significant strides with several notable partnerships:
- Unilabs, a prominent European diagnostic provider, adopted the SOPHiA DDM™ Platform to enhance their HRD-status testing capabilities in solid tumors.
- Syndicate Bio in Nigeria integrated MSK-ACCESS® powered by SOPHiA DDM™, marking the first comprehensive genomic profiling and liquid biopsy availability across Africa.
- Klinikum Klagenfurt in Austria and Instituto Mário Penna in Brazil have also implemented the platform to advance their cancer diagnostics and treatment planning, particularly in blood-related cancers and disorders.
Financially, SOPHiA GENETICS is recognized for its robust operational execution and business momentum, continually reaffirming its guidance. The company is actively collaborating with tech giants like Microsoft and NVIDIA to develop a streamlined whole genome sequencing (WGS) analytical solution, promising rapid and precise insights aiding clinical decision-making.
SOPHiA GENETICS also launched SOPHiA UNITY, a global consortium to accelerate cancer research by harnessing diverse, high-quality data from leading institutions worldwide. The platform’s advanced AI-based technology and proprietary algorithms will support decision-making and expedite oncology research.
For more information, visit SOPHiAGENETICS.com or connect on LinkedIn, X, Facebook, and Instagram.
SOPHiA GENETICS (NASDAQ: SOPH) announced a partnership with the University of Arkansas for Medical Sciences (UAMS) to implement the SOPHiA DDM™ platform for clinical oncology research, focusing on hematologic malignancies. This cloud-native platform harnesses AI to analyze next-generation sequencing (NGS) data, allowing for swift insights into blood cancers like leukemia and lymphoma. The collaboration aims to enhance local expertise and quicken data turnaround for clinical researchers, ultimately benefiting patient care in Arkansas, where these cancers rank as the fourth most common type.
QIAGEN N.V. (NYSE: QGEN) has launched the QIAseq Platform Partnership with SOPHiA GENETICS (NASDAQ: SOPH), aimed at improving the compatibility of QIAGEN's NGS kits with digital data-sharing platforms. This collaboration will enable somatic variant detection using QIAseq panels for homologous recombination repair, enhancing research in precision diagnostics. The partnership is set to expand to custom solutions, allowing greater access to data-driven medicine. Notably, QIAGEN has processed about four million samples with their NGS panels, solidifying their position in the genomics market.
SOPHiA GENETICS (Nasdaq: SOPH) has entered into a partnership with QIAGEN (NYSE: QGEN) to integrate QIAseq reagent technology with its SOPHiA DDM™ platform. This collaboration aims to enhance tumor analysis through next-generation sequencing (NGS), specifically supporting somatic variant detection related to homologous recombination repair. The partnership allows customers to access QIAseq panels for improved data analysis, enhancing research capabilities in oncology. Both companies are optimistic about the positive impact on medicine and research.
SOPHiA GENETICS (NASDAQ: SOPH) has announced a collaboration with Synergy Oncology to utilize SOPHiA DDM™ for a new cancer profiling solution named Totality. This innovative partnership aims to enhance the U.S. oncology market by integrating state-of-the-art laboratory technologies. SOPHiA DDM™ employs artificial intelligence to streamline complex data analysis, providing actionable insights for hereditary cancer treatments. Ken Freedman, Chief Revenue Officer, highlighted the significance of this collaboration in democratizing data-driven medicine. The combined technologies promise improved patient outcomes and align with both companies' missions to advance cancer research.
SOPHiA GENETICS (Nasdaq: SOPH) announced that it will release its financial results for Q4 and the full year of fiscal 2022 before the U.S. markets open on March 7, 2023. A conference call will follow at 8:00 a.m. EST to discuss these results and the company's business outlook. The call will be available via a live webcast on the SOPHiA GENETICS Investor Relations website, with a replay accessible afterward. The company focuses on data-driven medicine through its SOPHiA DDM™ Platform, enhancing healthcare solutions across global institutions.
SOPHiA GENETICS (Nasdaq: SOPH) is partnering with AstraZeneca (Nasdaq: AZN) to enhance precision oncology through its SOPHiA DDM™ platform and multimodal technology. This collaboration aims to improve early patient identification, optimize clinical development, and accelerate the use of innovative treatments. The partnership will integrate various data modalities, including radiomics, molecular data, and clinical information, to provide better insights for treatment decisions. Additionally, SOPHiA is conducting its own DEEP-Lung-IV clinical study to identify predictive signatures for lung cancer immunotherapy response.
SOPHiA GENETICS (NASDAQ: SOPH), a cloud-native software company, has partnered with Memorial Sloan Kettering Cancer Center (MSK) to enhance cancer testing and analytics. This collaboration focuses on the MSK-ACCESS® sequencing tests, the first comprehensive ctDNA liquid biopsy test leveraging the SOPHiA DDM™ Platform. Both parties aim to develop a clinico-genomic analytics platform, utilizing advanced machine learning to improve global cancer care. The partnership was announced ahead of the 41st annual JP Morgan Healthcare Conference on January 10, 2022.
SOPHiA GENETICS (NASDAQ: SOPH) announced that CEO Dr. Jurgi Camblong will present at the J.P. Morgan 2023 Healthcare Conference on January 10, 2023, at 8:15 a.m. PST in
SOPHiA GENETICS (Nasdaq: SOPH) reported Q3 2022 revenue of $11.6 million, a 12% increase year-over-year, with constant currency growth of 40% excluding COVID-19 revenues. The company improved its operating loss to $23.6 million, reflecting progress in its sustainable growth strategy. Gross profit rose to $7.3 million, maintaining a gross margin of 63%. Total operational expenses increased to $30.9 million. For full-year 2022, SOPHiA expects revenue to be at the low-end of the guidance range of $47.0 million to $49.5 million due to foreign exchange factors.
FAQ
What is the current stock price of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
What is the market cap of SOPHiA GENETICS SA Ordinary Shares (SOPH)?
What does SOPHiA GENETICS do?
What is the SOPHiA DDM™ Platform?
Where is SOPHiA GENETICS based?
Who are some of SOPHiA GENETICS' partners?
What is SOPHiA UNITY?
How does SOPHiA GENETICS support precision medicine?
What recent advancements have SOPHiA GENETICS made?
What is the company's mission?
How does SOPHiA GENETICS ensure data privacy and quality?
How can I learn more about SOPHiA GENETICS?
